NCT04314986View on ClinicalTrials.gov

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

September 18, 2019

Study Completion Date

September 18, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Cohort 1: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days

DRUG

Cohort 2: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days.

DRUG

Cohort 3: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days

DRUG

Cohort 4: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days

Trial Locations (1)

3004

Nucleus Network Pty, Ltd., Melbourne

Sponsors
All Listed Sponsors
lead

Arthrosi Therapeutics

INDUSTRY

NCT04314986 - Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers | Biotech Hunter | Biotech Hunter